Treatment of Bone Metastases from Breast Cancer with APD
Author Information
Author(s): R.E. Coleman, P.J. Woll, M. Miles, W. Scrivener, R.D. Rubens
Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital, London, UK
Hypothesis
Can APD therapy effectively treat bone metastases in breast cancer patients?
Conclusion
APD therapy can inhibit bone destruction and improve both subjective and objective responses in patients with bone metastases from breast cancer.
Supporting Evidence
- Radiological evidence of bone healing was seen in 4 patients.
- The median duration of response was 10 months.
- 11 patients had stable disease for at least 3 months.
- 9 patients experienced symptomatic response.
- 12 patients reported an improvement in quality of life.
- APD was well tolerated with no significant toxicity.
Takeaway
This study shows that a medicine called APD can help people with bone problems caused by breast cancer, making them feel better and live longer.
Methodology
Patients received APD 30mg in saline every 14 days, and their responses were assessed using UICC criteria and a pain questionnaire.
Limitations
The study did not include other systemic treatments, which may limit the generalizability of the results.
Participant Demographics
Median age of participants was 52 years, with a range from 32 to 73 years.
Want to read the original?
Access the complete publication on the publisher's website